Significant scientific rigour underpins the development of all QBiotics pharmaceuticals.  The dissemination of this research through publication in peer reviewed journals is a priority for the company.  The timing of the release of this information into the public domain is critical to both protect the intellectual property of QBiotics as well as to optimise opportunities for market launch of registered products.  Intellectual property protection via patenting has been successfully implemented with granting in all major regions and patents for our wound healing pharmaceutical are currently under examination.  As such, publication of our data is now underway. 

Our publication plan for tigilanol tiglate addresses all the key scientific investigations completed in the drug's development including its mode of action, chemical characterization, clinical efficacy and safety profile (for both veterinary and human products) and research associated with domestication of the source plant.  Ongoing publication of research and development will build upon the existing published data creating intellectual assets to support the imminent veterinary market launches as well as to support its clinical development in humans.  This approach will be implemented for all other pharmaceuticals in the QBiotics product pipeline.


Publications and Presentations

  1. Melo SR et al 2017. Time-assessed infra-red thermal characterization of canine cutaneous mast cell tumours (cMCT) treated intratumorally with the investigational anticancer agent tigilanol tiglate (EBC-46). Veterinary Cancer Society, Portland USA
  2. Boyle G 2017. Mechanism of action of Tigilanol tiglate (EBC-46), a novel anti-cancer agent
  3. Lowden S 2017. Tigilanol tiglate (EBC-46), a new tool in the anti-solid surface tumours tool box?
  4. Grant EL 2017. Floral and reproductive biology of the medicinally significant rainforest tree, Fontainea picrosperma (Euphorbiaceae) Elecktra L. Grant et al. Industrial Crops & Products 108 (2017) 416-422
  5. Boyle G et al. 2014. Intra-lesional Injection of the Novel PKC Activator EBC-46 Rapidly Ablates Tumors in Mouse Models, PLOS ONE, Vol 9, Issue 10
  6. Campbell J et al 2017. Using triamcinolone in combination with the investigational anticancer agent EBC-46 (tigilanol tiglate) in the local treatment of a canine subcutaneous mast cell tumour. Campbell, Justine et al. C&T No. 5598
  7. Barnett C et al. Optimising intratumoral treatment of head and neck squamous cell carcinoma models with the diterpene ester Tigilanol tiglate. Investigational New Drugs; April 2018